DreamUpVision retina

Our Challenge

How can we help to the ophthamologists to accelerate the screening of retinal diseases in order to detect disorders at their early stage?

Our Technology

DreamUp Vision builds an innovative retinal analysis engine based on the state-of-the art machine learning known as deep learning. It performs a quick detection of complicated patterns in retinal images.

Our Solution

Our solutions is a Saas platform which can be used by Healthcare professionals staying in permanent contact with a diabetic patient. They facilitate early diagnosis of the different retinal disorders.

Our Challenge

icon
icon
icon

  • The total number of blind people is about 39 million, and of the visually impaired is approximately 285 million. The leading causes are cataract, glaucoma, macular degeneration, corneal opacities, diabetic retinopathy and eye conditions in children. The preventable causes of visual impairment are approximately 80% of the total cases. Early diagnosis plays an invaluable role in such cases.
  • Diabetic retinopathy (DR) is the major cause for the blindness in the working-age population. Diabetic retinopathy is caused by diabetes. Statistically more than 75% of people who had diabetes for more than 20 years will have some form of DR.
  • The early detection of DR could prevent blindness. The problem is that DR usually shows no symptoms before the later stages where the blindness cannot be avoided. The early diagnosis in the blood vessels of the retina can be made through regular retina monitoring. The regular retina analysis of diabetic patients is a worldwide problem, because nearly 3 million eyes will need to be evaluated by the ophthalmologists each day by 2030 (35 exams per second).
  • Another problem is the decrease of the number of ophthalmologists. We have a 54 % increase in the diabetes population against 2% growth in the number of ophthalmologists for 2030.
  • Besides, most people (80%) with diabetes live in low-income countries where the ophthalmologists are hardly accessible. In developed countries diabetic patients are supposed to visit an ophthalmologist each year, but in practice they do it even each 2-5 years which prevents early detection of the retina disorders.

DreamUp Vision is aiming to help the healthcare professionals benefit from the latest advances in machine learning to create better retinal screening in order to detect the eye diseases at their early stage. .

Our technology

Our solutions

  • DreamUp Vision has developed a cognitive learning engine which relies on deep-learning technologies. This engine is a powerful tool in the image analysis and the detection of the disorders. Our technology allows us detection of the stages of retinopathy with the performances of the professional ophthalmologists in milliseconds. This engine can be implemented both the online web-application as mobile application, or integrated directly into fundus camera. The retinal photo can be provided from any fundus camera. It can be analyzed online from any location, including from the retinopathy telemedicine centers existing in some countries. In these centers, the patients can take an appointment in order to have a retina photo taken by nurses or orthoptists. These photos are then sent to professional ophthalmologists in order to be analyzed. Our solution could analyse the image directly at the center and thus to palliate to the leakage of ophthalmologists.
icon

Type

Saas platform and embedded solution linked to a visual recognition system able to distinguish the presence of a retinal abnormality on the basis of a fundus photo.

Goals

  • Screening
  • Diagnostics
  • Monitoring
  • Improvement of care

Targets

  • general practitioners
  • diabetologists
  • opticians
  • ophthalmologists
  • orthoptists
  • nurses

Our Team

team-member

Ekaterina Retinskaya-Besse, PhD

Chief Executive Officer and Founder

Ekaterina is CEO and Founder of DreamUp Vision. Ekaterina has a PhD degree in Theoretical Physics (2014). During her PhD studies at the Institut de Physique Théorique of the CEA Saclay, she was studying and developing theoretical models to describe the state of matter called quark-gluon plasma created in heavy-ion collisions at the LHC (CERN, Geneva) and RHIC (BNL, Brookhaven) colliders. After her PhD, she joined DreamQuark as Chief Operating Officer and was developing deep learning algorithms. Ekaterina became responsible for DreamUp Vision project in 2015 at DreamQuark, and in 2016 has founded DreamUp Vision as an independent company.
During her school career, in 2005 Ekaterina won an international competition in Mathematics and Physics and was accepted into Lomonosov Moscow State University without examination with the highest score. During her studies in the Physics department of Lomonosov Moscow State University, she won numerous prizes for the best students (rating Top-10 among 450 students of the promotion) and graduated with the degree of Masters in Nuclear and Particle Physics, awarded with the "red" diploma issued to the best students of the promotion (2011). After her Masters she has won a grant CFR of CEA Saclay, and moved to France to do her PhD studies.
At her free time, she plays piano (diploma with honours of 7-years music school), and practices sports and dancing.
Ekaterina is a former President of the R&D commission (2015) and an actual Administrator (2016) of France eHealthTech, association that unites startups in the sector of e-Health and well-being in France.

team-member

Adrien Besse, PhD

Associate, Chief Technology Officer

PhD in Theoretical Physics, Former student of Ecole Normale Supérieure of Lyon ("normalien"), M2 in Theoretical Physics of ENS Ulm, Adrien is Chief Technology Officer of DreamUp Vision company from 2016. With an experience of one year postdoctoral fellowship at the Service of Physique Nucléaire of the CEA Saclay in 2013-2014 and the PhD at the Laboratoire de Physique Théorique of Orsay (2013), his competences in Theoretical Physics as well as in Mathematics are the necessary asset in the development of the Artificial Intelligence engine and of the statistical models. In 2014 Adrien joined DreamQuark as a Chief Research Officer where he was responsible for research aspects of deep-learning algorithms, and in 2015 he became technical responsible for DreamUp Vision, where he plays a role of CTO from 2016. Adrien has several years experience in deep-learning field.
Adrien is passionate about sports, and is practicing "chistera" (national bask sport) in the National French Leage of Chistera. Adrien is also playing classic and electric guitar.

Board members and advisors

team-member

Nicolas Meric, PhD

Co-founder, Strategy advisor

Nicolas is the co-founder of DreamUp Vision and the founder of DreamQuark. After finishing a PhD in Particle Physics (2013) at CERN (Atlas experiment), CEA Saclay and LPTHE, Nicolas decided to apply what he has learned and developed during his PhD studies to help insurance and healthcare companies to better use their data in order to provide better predictive models, prevention and diagnosis with the help of deep-learning algorithms and created DreamQuark in March 2014. Nicolas is advising DreamUp Vision on the business develoment.

team-member

Tram TRINH, MBA, CPA

Board Member & Vice President Global Alliances

With 20-year international corporate experience in North America, Europe and Asia, Tram is passionate about market creation. Today Tram helps digital health medtech start-ups or SMEs that want to expand in Europe shape their strategy, land their ideal customers or their next strategic milestone. Rapid results are achieved with her “door- opener” process. Tram Trinh founded VITAnLINK with one mission: instill hands-on & timely execution, grow and build out-of-the-box opportunities for/with the best people in the digital health medtech landscape. Prior to VITAnLINK, she was instrumental in shaping new services within the MedTech & Diagnostics industry. At Johnson&Johnson OCD, she took the responsibility of Project Leader France for the CEO office, then moved to Market Development Director France and to Europe Middle East and Africa Head Marketing Services with 2 J&J Standards of leadership Awards joining also the J&J International "High-Po" Pool. In 2009, she was Welch Allyn General Manager looking after the French speaking countries to create, expand, structure markets & teams including launching the company’s first connected vital signs devices in Europe. Prior to her healthcare journey, she co-structured in 1994 Ernst&Young Audit’s first business in Vietnam & Cambodia before joining the EY Paris office. She also co-founded motion waves start-up. She had been a long time member of the CJD network of French Entrepreneurs and teaching moderator at the CNAM Art et Métiers Innovation Management Program. Tram is one of the founding executive members at Avenir Femmes Santé, a French Not-For-Profit Association for women’s health. She is also a Mentor and Advisory Board Member at key European, Israeli and North American health startup Accelerators and European Patient Associations. She holds an MBA from McGill University Canada, an Executive Management Certificate from Columbia University and an American CPA license from New Hampshire Board of Accounting, US. She is on the Board of the IPEL Ivy Plus European Leaders international think tank and a NextGen member at AmCham France. Tram lives in Paris and loves Tai Chi.

team-member

Dr. Edouard Colas

Chief Medical Officer

Ophthalmologist at the 15-20 ("Quinze-Vingts") French National Ophtalmic Center in Paris, France. Fellow of the European Board of Ophthalmology, he received the MD degree from Pierre et Marie Curie Paris University in 2013. He is specialized in medical and surgical retinal diseases, trains ophthalmology residents and has participated in several books and scientific papers. He is also the ophtalmology expert of MeltingDoc, the first app which connects French doctors and helps them solve complex medical cases.

team-member


Armen Verdian, MBA

Board member, Strategy advisor

Co-founder of GA Partners, an independent M&A firm, Armen is also the co-founder of several start-ups, in particular CellProthera, a French biotech company specialized in heart regeneration through injection of autologous hematopoietic stem cells; and Quintesens, a brand of innovative and organic nutritional food products. He is also an early investor and board member of DreamQuark and Wakie.

team-member

Axel Orgogozo

Associate, Deep learning and Data analysis expertise

Axel is Chief Technology Officer of DreamQuark and provides DreamUp Vision with his high-quality expertise on Deep Learning and Computer vision expertise. Axel has done his PhD work at the Laboratoire de Physique theorique of the Ecole Normale Superieure of Paris in Theoretical Particle Physics. His analytical and programming skills are an important asset to develop deep learning technics and to study innovative technologies. Axel also develops 3D-graphics for computer games in his free time.

Collaborations, partnerships, accelerators

Awards

Blogs

To see our recent news and events, follow us on twitter!

Contact

IF YOUR ARE INTERESTED IN JOINING OUR COMPANY AS:

  • A PARTNER: We are interested in the parthnerships and scientific advisory of healthcare professionals, hospitals and laboratories in order to face the challenge together. If you are interested in our solution, please contact us.
  • AN INVESTOR: If you want to invest in our company, we are looking for investors who share our values. Any investor eager to participate to our endeavour will be warmly welcome.
  • A TEAM MEMBER: We are looking for bright, enthusiastic and highly-motivated individuals with a passion for complex challenges. If you feel you have the grit to join our team, then contact us.


DREAMUPVISION SAS

SIRET: 82098604000013

HQ : 74 RUE DU FAUBOURG SAINT ANTOINE 75012 PARIS

OFFICES : 23 AVENUE D'ITALIE, 75013 PARIS